GRAIL (GRAL) Could Be 5% Overvalued As FDA Review Date Sharpens Focus

Simply Wall St.08-09 12:34

AdvertisementRegulatory milestone puts focus on GRAIL stock GRAIL (GRAL) is in the spotlight after the FDA scheduled a September 23, 2026 advisory committee meeting to review the Premarket Approval ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2658679762?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-08-09 12:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2658679762","market":"nz","top_or_hot":-1,"title":"GRAIL (GRAL) Could Be 5% Overvalued As FDA Review Date Sharpens Focus","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementRegulatory milestone puts focus on GRAIL stock GRAIL (GRAL) is in the spotlight after the FDA scheduled a September 23, 2026 advisory committee meeting to review the Premarket Approval ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-gral/grail/news/grail-gral-could-be-5-overvalued-as-fda-review-date-sharpens\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GRAIL (GRAL) Could Be 5% Overvalued As FDA Review Date Sharpens Focus</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGRAIL (GRAL) Could Be 5% Overvalued As FDA Review Date Sharpens Focus\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-08-09 12:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-gral/grail/news/grail-gral-could-be-5-overvalued-as-fda-review-date-sharpens><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementRegulatory milestone puts focus on GRAIL stock GRAIL (GRAL) is in the spotlight after the FDA scheduled a September 23, 2026 advisory committee meeting to review the Premarket Approval ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-gral/grail/news/grail-gral-could-be-5-overvalued-as-fda-review-date-sharpens\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GRAL","symbol_name":"GRAIL, Inc.","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-gral/grail/news/grail-gral-could-be-5-overvalued-as-fda-review-date-sharpens","article_id":"2658679762","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-gral/grail/news/grail-gral-could-be-5-overvalued-as-fda-review-date-sharpens","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2658679762","pubTimestamp":1786250074,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Regulatory milestone puts focus on GRAIL stock\nGRAIL (GRAL) is in the spotlight after the FDA scheduled a September 23, 2026 advisory committee meeting to review the Premarket Approval application for its Galleri multi cancer early detection blood test.\nSee our latest analysis for GRAIL.\nThe FDA panel date has come alongside GRAIL’s recent Q2 update and a sharp 1 day share price return of 9.59%, even though the year to date share price return is down 21.82%. Over the past year, the total...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"GRAL":"GRAIL, Inc.","LABU":"三倍做多标普生物-Direxion","BK4139":"生物科技","BK4588":"碎股","BK4585":"ETF&股票定投概念"},"translate_title":"随着 FDA 审查日期加剧关注，GRAIL (GRAL) 可能被高估 5%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GRAL":1.5,"LABU":1.5},"content_text":"AdvertisementRegulatory milestone puts focus on GRAIL stock GRAIL (GRAL) is in the spotlight after the FDA scheduled a September 23, 2026 advisory committee meeting to review the Premarket Approval application for its Galleri multi cancer early detection blood test. See our latest analysis for GRAIL. The FDA panel date has come alongside GRAIL’s recent Q2 update and a sharp 1 day share price return of 9.59%, even though the year to date share price return is down 21.82%. Over the past year, the total shareholder return of 111.70% contrasts with a softer 30 day share price return, which suggests strong longer term momentum while more recent trading has cooled. If this regulatory milestone has you thinking more broadly about healthcare and AI, it may be a good moment to scan for other opportunities using our healthcare focused stock screener for 43 healthcare AI stocks For GRAIL, the 1 day jump and softer recent returns sit alongside growing revenue and ongoing losses. Is this latest move a reaction to improving fundamentals, or a swing in sentiment ahead of the FDA review and pricing assumptions? Most Popular Narrative: 5.3% Overvalued The most followed narrative values GRAIL at $66 per share, slightly below the last close at $69.48, which suggests the market is paying a premium for the story today.  Ongoing positive clinical trial results, including substantially higher cancer detection and positive predictive value with consistent specificity for Galleri in population-scale studies, are setting the stage for robust FDA approval and broad payer reimbursement, which could unlock significant new revenue streams and accelerate top-line growth.  Read the complete narrative. Curious what kind of revenue ramp, margin shift, and future earnings multiple are baked into that fair value? The narrative leans on bold assumptions. The details may surprise you. Result: Fair Value of $66 (OVERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, GRAIL’s sustained losses and the uncertainty around FDA and payer decisions on Galleri could quickly challenge this overvaluation story if market sentiment changes. Find out about the key risks to this GRAIL narrative. Next Steps With both risks and rewards in play for GRAIL, it helps to move quickly from headlines to hard numbers and form your own judgment using the full breakdown of 2 key rewards and 3 important warning signs Looking for more GRAIL investment ideas? If GRAIL has sharpened your focus on opportunities, do not stop here. Use targeted stock lists to pressure test your thinking and spot ideas you might otherwise miss.  Target potential mispricings by scanning companies that appear attractively valued using the 51 high quality undervalued stocks. Prioritize resilience by checking out the 79 resilient stocks with low risk scores and see which stocks score well on stability. Hunt for less crowded ideas through the screener containing 19 high quality undiscovered gems before others start paying attention.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"-1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2658679762","isCrawlerRequest":true}